Kane Biotech Receives Health Canada Approval for revyve(TM) Antimicrobial Wound Gel Spray

Executive Summary

• Health Canada approved Kane Biotech’s revyve® Antimicrobial Wound Gel Spray for use in Canada.
• The spray, already FDA 510(k) cleared, adds a new wound‑care option for burns, large surface‑area wounds and ulcers in the Canadian market.
• Interim CEO Dr. Robert B. Huizinga highlighted the approval as validation of clinical data and a step forward for patients with chronic or hard‑to‑heal wounds.

Key Details

• Regulatory Milestone: Health Canada approval follows prior FDA 510(k) clearance, marking the first Canadian market authorization for revyve® Antimicrobial Wound Gel Spray.
• Product Purpose: Designed to reduce microbial burden and promote healthier wound environments in complex wounds (burns, large surface‑area wounds, ulcers).
• Clinical Background: The spray is part of Kane’s revyve portfolio, which has been evaluated in multiple U.S. clinical settings.
• Market Impact: Enables Canadian clinicians and patients to access a novel antimicrobial wound‑care option; company will work with healthcare partners and distributors for rollout and education.
• Pipeline Update: Kane Biotech recently submitted an FDA filing for revyve Antimicrobial Wound and Skin Cleanser, the third product in its revyve line.

Notable Quotes

“Health Canada’s approval of the revyve Antimicrobial Wound Gel Spray is another step forward in our mission to improve outcomes for patients with chronic and hard‑to‑heal wounds. This approval validates the strength of our clinical data and provides Canadian healthcare providers with a new tool to address the burden of wound infections.” – Dr. Robert B. Huizinga, Interim CEO, Kane Biotech

Materiality: Material – Positive (regulatory approval expands market access and supports revenue growth potential).